Induction chemotherapy-based larynx preservation program for locally advanced hypopharyngeal cancer: oncologic and functional outcomes and prognostic factors
- PMID: 26858198
- DOI: 10.1007/s00405-016-3919-3
Induction chemotherapy-based larynx preservation program for locally advanced hypopharyngeal cancer: oncologic and functional outcomes and prognostic factors
Abstract
To evaluate oncologic and functional outcomes and prognostic factors in patients with locally advanced hypopharyngeal cancer included in an induction chemotherapy (ICT)-based larynx preservation program in daily clinical practice. All patients with locally advanced (T3/4, N0-3, M0) hypopharyngeal squamous cell carcinoma, technically suitable for total pharyngo-laryngectomy, treated by docetaxel (75 mg/m(2), day 1), cisplatin (75 mg/m(2), day 1) and 5-fluorouracil (750 mg/m(2)/day, day 1-5) (TPF)-ICT (2-3 cycles) for larynx preservation at our institution between 2004 and 2013, were included in this retrospective study. Prognostic factors of oncologic (overall, cause-specific and recurrence-free survival: OS, SS and RFS) and functional (dysphagia outcome and severity scale, permanent enteral nutrition, larynx preservation) outcomes were assessed in univariate and multivariate analyses. A total of 53 patients (42 men and 11 women, mean age 58.6 ± 8.2 years) were included in this study. Grade 3-4 toxicities were experienced by 17 (32 %) patients during ICT. The rate of poor response (response <50 % without larynx remobilization) to ICT was 10 %. At 5 years, OS, SS and RFS rates were 56, 60 and 54 %, respectively. Four patients required definitive enteral nutrition (permanent enteral tube feeding). The rate of patients alive, disease-free and with a functional larynx at 2 years was 58 %. T4 tumor stage (p = 0.005) and response to ICT <50 % (p = 0.02) were independent prognostic factors of OS. Response to ICT was significantly associated with the risk of permanent enteral nutrition (p = 0.04) and larynx preservation (p = 0.01). In daily clinical practice, a TPF-ICT-based larynx preservation protocol can be used in patients with locally advanced hypopharyngeal cancer with satisfactory results in terms of tolerance, efficacy and oncologic and functional outcomes.
Keywords: Cancer; Functional outcome; Hypopharynx; Induction chemotherapy; Larynx preservation; Prognosis.
Similar articles
-
Nutritional status and feeding-tube placement in patients with locally advanced hypopharyngeal cancer included in an induction chemotherapy-based larynx preservation program.Eur Arch Otorhinolaryngol. 2016 Sep;273(9):2681-7. doi: 10.1007/s00405-015-3785-4. Epub 2015 Sep 22. Eur Arch Otorhinolaryngol. 2016. PMID: 26395117
-
Long-term Results of a Multicenter Randomized Phase III Trial of Induction Chemotherapy With Cisplatin, 5-fluorouracil, ± Docetaxel for Larynx Preservation.J Natl Cancer Inst. 2015 Dec 16;108(4):djv368. doi: 10.1093/jnci/djv368. Print 2016 Apr. J Natl Cancer Inst. 2015. PMID: 26681800 Clinical Trial.
-
Could the Addition of Cetuximab to Conventional Radiation Therapy Improve Organ Preservation in Those Patients With Locally Advanced Larynx Cancer Who Respond to Induction Chemotherapy? An Organ Preservation Spanish Head and Neck Cancer Cooperative Group Phase 2 Study.Int J Radiat Oncol Biol Phys. 2017 Mar 1;97(3):473-480. doi: 10.1016/j.ijrobp.2016.11.016. Epub 2016 Nov 17. Int J Radiat Oncol Biol Phys. 2017. PMID: 28011050 Clinical Trial.
-
Induction Chemotherapy With 5-Fluorouracil, Cisplatin, and Cetuximab in Advanced Head and Neck Squamous Cell Carcinoma.In Vivo. 2023 May-Jun;37(3):1275-1280. doi: 10.21873/invivo.13205. In Vivo. 2023. PMID: 37103108 Free PMC article. Review.
-
Larynx preservation clinical trial design: key issues and recommendations-a consensus panel summary.Int J Radiat Oncol Biol Phys. 2009 Apr 1;73(5):1293-303. doi: 10.1016/j.ijrobp.2008.10.047. Int J Radiat Oncol Biol Phys. 2009. PMID: 19306746
Cited by
-
Preserving Laryngo-Esophageal Function in Patients With Hypopharyngeal Cancer Treated With Radiotherapy: Predictive Factors and Long-Term Outcomes.Cancer Med. 2024 Nov;13(21):e70374. doi: 10.1002/cam4.70374. Cancer Med. 2024. PMID: 39487662 Free PMC article.
-
Nimotuzumab Combined with Induction Chemotherapy and Concurrent Chemoradiotherapy in Unresectable Locally Advanced Hypopharyngeal Carcinoma: A Single Institution Experience in China.Cancer Manag Res. 2020 May 11;12:3323-3329. doi: 10.2147/CMAR.S248392. eCollection 2020. Cancer Manag Res. 2020. PMID: 32494195 Free PMC article.
-
Nursing Observation on the Clinical Efficacy and Toxicity of Lobaplatin Compared with Cisplatin in the Treatment of Locally Advanced Hypopharyngeal Carcinoma Based on Intelligent CT Imaging.J Healthc Eng. 2021 Jun 30;2021:9982888. doi: 10.1155/2021/9982888. eCollection 2021. J Healthc Eng. 2021. Retraction in: J Healthc Eng. 2023 Jan 19;2023:9846052. doi: 10.1155/2023/9846052. PMID: 34306603 Free PMC article. Retracted.
-
Functional Larynx Preservation in Patients With Locally Advanced Squamous Cell Carcinoma of the Larynx and Hypopharynx Treated With Induction Chemotherapy vs. Concurrent Chemoradiation Alone.Cureus. 2021 Jul 11;13(7):e16310. doi: 10.7759/cureus.16310. eCollection 2021 Jul. Cureus. 2021. PMID: 34405069 Free PMC article.
-
Construction of a novel six-gene signature to predict tumour response to induction chemotherapy and overall survival in locoregionally advanced laryngeal and hypopharyngeal carcinoma.Genes Dis. 2023 Jul 16;11(3):101022. doi: 10.1016/j.gendis.2023.05.018. eCollection 2024 May. Genes Dis. 2023. PMID: 38292204 Free PMC article. No abstract available.
References
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical